1. Home
  2. NAMS vs POWI Comparison

NAMS vs POWI Comparison

Compare NAMS & POWI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • POWI
  • Stock Information
  • Founded
  • NAMS 2019
  • POWI 1988
  • Country
  • NAMS Netherlands
  • POWI United States
  • Employees
  • NAMS N/A
  • POWI N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • POWI Semiconductors
  • Sector
  • NAMS Health Care
  • POWI Technology
  • Exchange
  • NAMS Nasdaq
  • POWI Nasdaq
  • Market Cap
  • NAMS 2.7B
  • POWI 2.6B
  • IPO Year
  • NAMS N/A
  • POWI 1997
  • Fundamental
  • Price
  • NAMS $26.73
  • POWI $45.57
  • Analyst Decision
  • NAMS Strong Buy
  • POWI Strong Buy
  • Analyst Count
  • NAMS 10
  • POWI 3
  • Target Price
  • NAMS $41.40
  • POWI $61.67
  • AVG Volume (30 Days)
  • NAMS 984.0K
  • POWI 534.5K
  • Earning Date
  • NAMS 11-05-2025
  • POWI 11-05-2025
  • Dividend Yield
  • NAMS N/A
  • POWI 1.84%
  • EPS Growth
  • NAMS N/A
  • POWI N/A
  • EPS
  • NAMS N/A
  • POWI 0.59
  • Revenue
  • NAMS $64,006,000.00
  • POWI $442,468,000.00
  • Revenue This Year
  • NAMS N/A
  • POWI $11.06
  • Revenue Next Year
  • NAMS $1.67
  • POWI $14.36
  • P/E Ratio
  • NAMS N/A
  • POWI $77.25
  • Revenue Growth
  • NAMS 762.15
  • POWI 7.16
  • 52 Week Low
  • NAMS $14.06
  • POWI $39.53
  • 52 Week High
  • NAMS $27.35
  • POWI $69.53
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 59.23
  • POWI 48.00
  • Support Level
  • NAMS $23.05
  • POWI $44.27
  • Resistance Level
  • NAMS $27.35
  • POWI $46.23
  • Average True Range (ATR)
  • NAMS 1.52
  • POWI 1.32
  • MACD
  • NAMS -0.11
  • POWI 0.26
  • Stochastic Oscillator
  • NAMS 85.58
  • POWI 77.84

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About POWI Power Integrations Inc.

Power Integrations Inc designs, develops, and markets analog and mixed-signal integrated circuits (ICs) and other electronic components and circuitry used in high-voltage power conversion. Products are used in power converters that convert electricity from a high-voltage source to the type of power required for a specified downstream use. Products are used in electronic products including mobile phones, computing and networking equipment, appliances, electronic utility meters, battery-powered tools, industrial controls, home automation, or Internet of Things applications such as networked thermostats, power strips, and security devices. Geographically, the company generates maximum revenue from China and Hong Kong.

Share on Social Networks: